Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes

转移性淋巴结中,人类区域淋巴结中针对癌症免疫疗法的动态 CD8+ T 细胞反应受到破坏。

阅读:3
作者:Maha K Rahim ,Trine Line H Okholm ,Kyle B Jones ,Elizabeth E McCarthy ,Candace C Liu ,Jacqueline L Yee ,Stanley J Tamaki ,Diana M Marquez ,Iliana Tenvooren ,Katherine Wai ,Alexander Cheung ,Brittany R Davidson ,Vrinda Johri ,Bushra Samad ,William E O'Gorman ,Matthew F Krummel ,Annemieke van Zante ,Alexis J Combes ,Michael Angelo ,Lawrence Fong ,Alain P Algazi ,Patrick Ha ,Matthew H Spitzer

Abstract

CD8+ T cell responses are critical for anti-tumor immunity. While extensively profiled in the tumor microenvironment, recent studies in mice identified responses in lymph nodes (LNs) as essential; however, the role of LNs in human cancer patients remains unknown. We examined CD8+ T cells in human head and neck squamous cell carcinomas, regional LNs, and blood using mass cytometry, single-cell genomics, and multiplexed ion beam imaging. We identified progenitor exhausted CD8+ T cells (Tpex) that were abundant in uninvolved LN and clonally related to terminally exhausted cells in the tumor. After anti-PD-L1 immunotherapy, Tpex in uninvolved LNs reduced in frequency but localized near dendritic cells and proliferating intermediate-exhausted CD8+ T cells (Tex-int), consistent with activation and differentiation. LN responses coincided with increased circulating Tex-int. In metastatic LNs, these response hallmarks were impaired, with immunosuppressive cellular niches. Our results identify important roles for LNs in anti-tumor immune responses in humans. Trial registration: ClinicalTrials.gov NCT03708224.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。